Marshall Edwards Submits Investigational New Drug Application for Oncology Drug Candidate ME-344

Marshall Edwards, Inc.

, an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, announced today that it has submitted an Investigational New Drug (

) application to the U.S. Food and Drug Administration to initiate clinical testing for oncology drug candidate ME-344, the Company's lead mitochondrial inhibitor. "I am extremely proud of our clinical operations and pre-clinical research teams in reaching this important milestone, less than seven months since our IND for ME-143 was approved by the FDA to begin clinical testing," said Daniel P. Gold, Ph.D., President and Chief Executive Officer of Marshall Edwards. "We are prepared to initiate a Phase I clinical trial of intravenous ME-344 in patients with solid refractory tumors immediately following approval by the FDA."